Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2009-01-28 M&A Activity
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Other Report or Announcement
M&A Activity Classification · 95% confidence The document is a short regulatory filing (1795 chars) transmitted to the Israel Securities Authority and the Tel Aviv Stock Exchange. It explicitly states: "Attached hereto is a report on *Company announced an update to its December 8, 2008 press release regarding the Company's activities in seeking to acquire potential assets or to identify a company to merge into or with XTL*" and lists a PDF attachment. This structure—a brief announcement referencing an attached or linked document about a specific corporate action (merger/acquisition activity)—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the content specifically relates to merger/acquisition activities ('seeking to acquire potential assets or to identify a company to merge into or with XTL'), the more specific category is M&A Activity (TAR). However, the document itself is an announcement *of* the publication of the update, making RPA a strong candidate based on the 'MENU VS MEAL' rule. Given the subject matter is clearly M&A, and this is a formal regulatory update, I will classify it as TAR (M&A Activity) as the core subject matter is dominant, although RPA is plausible if the focus was purely on the act of publishing. Since the content describes the substance of the M&A update, TAR is the best fit for the subject matter.
2009-01-28 English
Immediate Report
Delisting Announcement Classification · 100% confidence The document is a formal announcement from XTL Biopharmaceuticals regarding receipt of a delisting notice from NASDAQ. It details the delisting decision, the reasons behind it, the timeline for appeal, and the company's intention to appeal. There are no financial statements, detailed financial data, or report contents included. The document is short (1557 characters) and serves as an official notice of the delisting event rather than a financial report or detailed regulatory filing. Therefore, it fits the definition of a Delisting Announcement (DLST).
2009-01-28 Hebrew (modern)
Immediate Report
Delisting Announcement Classification · 98% confidence The document is an 'Immediate Report' filed under Israeli Securities Authority regulations (Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000). The core content explicitly states that the company received a 'Staff Determination Letter from Nasdaq notifying the Company that the Company's American Depository Shares ("ADRs") would be delisted from Nasdaq on February 5, 2009'. This directly concerns the removal of the company's stock from an exchange. Therefore, the most appropriate classification is Delisting Announcement (DLST). The document length is short (1988 chars) and it announces an event rather than being the full report itself.
2009-01-28 English
Immediate Report
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd., dated December 30, 2008. It includes a response to a Nasdaq staff letter regarding the company's status as a public shell and announces the upcoming departure of the CEO. The document is relatively short (3524 characters) and primarily serves as a regulatory update rather than a full financial report. It does not contain detailed financial statements or substantive financial data. The Form 6-K is a periodic report for foreign private issuers to disclose material information but is not an annual or quarterly report itself. Given these factors and the nature of the content, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2008-12-31 Hebrew (modern)
Immediate Report
Report Publication Announcement Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, referencing Regulation 4 of the Securities Regulations. The core content states that the company has attached a report on a '6-K form filed by the Company with SEC' regarding two specific events: responding to an SEC request and the departure of the CEO. Since the document itself is an announcement about filing an SEC report (Form 6-K) and does not contain the full content of that report, it fits the definition of a general regulatory announcement or a report publication announcement. Given the nature of reporting an external filing (6-K) and the short length (1855 chars), it is best classified as a Report Publication Announcement (RPA) or, if RPA is too specific for an external filing announcement, the general Regulatory Filings (RNS) category. Since RPA specifically covers announcements regarding the publication of reports, and this announces the publication of a 6-K, RPA is the most precise fit among the options, although RNS is a strong fallback. I will select RPA as it directly relates to announcing the release of another document.
2008-12-31 English
Regulatory Filings 2008
Regulatory Filings
2008-12-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.